Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis

다국어 초록 (Multilingual Abstract)

Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literaturebased examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.

참고문헌 (Reference)

1 Chamuleau RA, "Which are the right cells to be used in a bioartificial liver?" 20 : 327-335, 2005

2 김세준, "Therapeutic potential of adipose tissue-derived stem cells for liver failure according to the transplantation routes" 대한외과학회 81 (81): 176-186, 2011

3 김명덕, "Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis" 생화학분자생물학회 46 : 1-10, 2014

4 Fallowfield JA, "Targeted treatments for cirrhosis" 8 : 423-435, 2004

5 Amin MA, "Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis : Egyptian study" 27 : 607-612, 2013

6 The Nordic Cochrane Centre, "Review Manager (RevMan). Version 5.3 for Windows" The Cochrane Collaboration 2013

7 Mohamadnejad M, "Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis" 33 : 1490-1496, 2013

8 Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement" 151 : 264-269, 2009

9 Wang L, "Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis" 28 : 85-92, 2013

10 El-Ansary M, "Phase II trial : undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis" 8 : 972-981, 2012

11 El-Ansary M, "Phase I trial : mesenchymal stem cells transplantation in end stage liver disease" 1 : 22-33, 2010

12 Mohamadnejad M, "Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis" 10 : 459-466, 2007

13 Salama H, "Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease" 5 : 70-, 2014

14 Kim G, "Overview and recent trends of systematic reviews and meta-analyses in hepatology" 20 : 137-150, 2014

15 Scottish Intercollegiate Guidelines Network, "Methodology checklist 2: controlled trials"

16 Erices A, "Mesenchymal progenitor cells in human umbilical cord blood" 109 : 235-242, 2000

17 Kharaziha P, "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection : a phase I-II clinical trial" 21 : 1199-1205, 2009

18 Campagnoli C, "Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow" 98 : 2396-2402, 2001

19 Zhang Z, "Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients" 27 : 112-120, 2012

20 Young HE, "Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors" 264 : 51-62, 2001

21 di Bonzo LV, "Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine : engraftment and hepatocyte differentiation versus profibrogenic potential" 57 : 223-231, 2008

22 Shi M, "Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients" 1 : 725-731, 2012

23 Jang YO, "Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis : a pilot study" 34 : 33-41, 2014

24 Baertschiger RM, "Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver" 4 : 6657-, 2009

25 Jung J, "Epigenetic alterations of IL-6/STAT3 signaling by placental stem cells promote hepatic regeneration in a rat model with CCl4-induced liver injury" 8 : 79-89, 2015

26 Higgins J, "Cochrane handbook for systematic reviews of interventions. Version 5.1.0 updated March 2011"

27 김나연, "Clinical applications of mesenchymal stem cells" 대한내과학회 28 (28): 387-402, 2013

28 Amer ME, "Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells" 23 : 936-941, 2011

29 Peng L, "Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B : short-term and long-term outcomes" 54 : 820-828, 2011

30 Wang L, "Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis" 23 : 2482-2489, 2014